Everyone in the medical field dreads the “non-compete” clause in their contracts. Highlighting the complex and contentious world of non-compete clauses within the medical field, Dr. David Lankford, a pediatric intensivist, made headlines after challenging a non-compete clause in his contract with Lutheran Medical Group in Indiana. His lawsuit not only raises questions about the legality and ethical implications of such clauses, but also tests a new state law regarding physician non-competes. Dr. David Lankford is joined by Alex Pantos, an associate attorney integral to his case, and who is representing him from the firm Delaney and Delaney based in IN. Together, they provide deep insights into the legal intricacies, broader implications for healthcare professionals, and the potential impact of this legal battle on the medical community. The nuances and debates surrounding this pivotal case that may reshape the landscape of physician contracts and professional mobility.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
